Small US Companies On Target At Half Year
Smaller US pharmaceutical and research companies are in the main on-target financially after the first six months of 1994.
Centocor second-quarter results in 1994 compare favorably with those of 1993, with the company reducing its loss. "From a financial standpoint, this quarter was right on target in terms of results from operations, cash burn, and cash in hand," said David Holveck, president and chief executive. "In addition, we are making tremendous progress with several key biopharmaceutical products," he added.
Cytogen said the decrease in revenue in the second quarter of 1994 was a result of not receiving license or contract revenue from CytoRad. In 1993 it had received $1.6 million from CytoRad for product development. Also during the second quarter, Cytogen resumed responsibilities for the US marketing rights for Onco-Scint, a diagnostic agent for colorectal and ovarian cancer, which was previously granted to Knoll of Germany.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze